← Back to Search

Prostaglandin Analog

Group 2: Normal tension glaucoma subjects with thick corneas for Normal Tension Glaucoma (NTG Trial)

Phase 4
Waitlist Available
Research Sponsored by Salus University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months post-treatment
Awards & highlights

NTG Trial Summary

This study is evaluating whether a drug called netarsudil can be used to treat glaucoma in people with thicker corneas and higher levels of corneal hysteresis.

Eligible Conditions
  • Normal Tension Glaucoma

NTG Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Post-treatment IOP
Secondary outcome measures
Post-treatment IOP change by CCT
Post-treatment IOP change by CH
Post-treatment change in CCT
+1 more

NTG Trial Design

2Treatment groups
Experimental Treatment
Group I: Group 2: Normal tension glaucoma subjects with thick corneasExperimental Treatment2 Interventions
NTG subjects with CCT > 540 nm will be randomized to receive either netarsudil or bimatoprost.
Group II: Group 1: Normal tension glaucoma subjects with thin corneasExperimental Treatment2 Interventions
NTG subjects with CCT ≤ 540 nm will be randomized to receive either netarsudil or bimatoprost.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Netarsudil
FDA approved
Bimatoprost
FDA approved

Find a Location

Who is running the clinical trial?

Salus UniversityLead Sponsor
14 Previous Clinical Trials
842 Total Patients Enrolled
Jingyun Wang, Ph.DStudy DirectorSalus University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma
2021. "Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04981886.
All > Intraocular Lens > Latisse
~31 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top